
Stryker Corporation
- Growing?
- Yes: revenue up 8% on a year earlier (quarter ended Sep 2026); earnings per share up 23% over the last four quarters.
- Expensive?
- Cheaper than usual: 33.3× trailing earnings; its five-year median is 41.9×. Priced 34% above the peer median of 24.8x.
- Analysts?
- 73% of 30 say buy; average 12-month target $340, 9% above today's price.
- Risky?
- About average for a large company: its price swung 33% over the past year (the S&P 500's 14%), and it fell as much as 33% since Nov 2021.
Stryker is a medical technology company that sells orthopaedic implants, surgical equipment, endoscopy systems, and neurotechnology products; it primarily generates revenue from the sale of medical devices/consumables and related capital equipment (with associated service/support) to hospitals and clinicians.
More about Stryker
Market Position
Stryker is a large-scale, diversified medtech supplier with differentiated platforms such as Mako SmartRobotics (robotic-assisted orthopaedic surgery), and it competes across orthopaedics, surgical/medical equipment, endoscopy, and neurovascular/neurosurgical markets through a broad portfolio and hospital relationships.
Key Segments
Stryker reports two operating segments: MedSurg and Neurotechnology and Orthopaedics (renamed from Orthopaedics and Spine).
How has the stock done?
Over the past month SYK rose 10.5%; the health care ETF (XLV) rose 9.2% and the S&P 500 fell 2.7%.
Over the past six months SYK rose 6.1%; the health care ETF (XLV) rose 28.8% and the S&P 500 rose 2.6%.
Over the past year SYK fell 15.0%; the health care ETF (XLV) rose 22.9% and the S&P 500 rose 10.8%.
Over five years SYK rose 18.2%; the health care ETF (XLV) rose 40.4% and the S&P 500 rose 62.0%.
From Jul 25, 2025 to Sep 24, 2026, the deepest drop from a high since Nov 2021
How much the price swings in a year; the S&P 500's was 14%
When the S&P 500 moves 1%, the stock has moved about 0.2% the same way
Show the earnings releases
| Released | Quarter | Revenue | EPS vs estimate | Stock, day after | 5 days after |
|---|---|---|---|---|---|
| Oct 29, 2026 | ended Sep 2026 | $6.5B (+8% vs a year earlier) | $3.52 vs $3.55 (missed) | −4.0% | +10.2% |
| Jul 30, 2026 | ended Jun 2026 | $6.6B (+9% vs a year earlier) | $3.69 vs $3.49 (beat) | −7.5% | −4.2% |
| Apr 30, 2026 | ended Mar 2026 | $6.0B (+3% vs a year earlier) | $2.60 vs $2.98 (missed) | −6.5% | −6.6% |
| Jan 29, 2026 | ended Dec 2025 | $7.2B (+11% vs a year earlier) | $4.47 vs $4.40 (beat) | +3.3% | +1.3% |
| Oct 30, 2025 | ended Sep 2025 | $6.1B (+10% vs a year earlier) | — | −3.6% | −4.3% |
| Jul 31, 2025 | ended Jun 2025 | $6.0B (+11% vs a year earlier) | — | −5.6% | −6.0% |
| May 1, 2025 | ended Mar 2025 | $5.9B (+12% vs a year earlier) | — | +1.1% | +2.3% |
| Jan 28, 2025 | ended Dec 2024 | $6.4B (+11% vs a year earlier) | — | −2.2% | −1.9% |
| Oct 29, 2024 | ended Sep 2024 | $5.5B (+12% vs a year earlier) | — | +2.1% | +3.9% |
| Jul 30, 2024 | ended Jun 2024 | $5.4B (+9% vs a year earlier) | — | −1.7% | −3.2% |
| Apr 30, 2024 | ended Mar 2024 | $5.2B (+10% vs a year earlier) | — | −3.2% | −2.0% |
| Jan 30, 2024 | ended Dec 2023 | $5.8B (+12% vs a year earlier) | — | +6.7% | +8.0% |
| Nov 2, 2023 | ended Sep 2023 | $4.9B (+10% vs a year earlier) | — | +1.5% | −0.4% |
| Aug 3, 2023 | ended Jun 2023 | $5.0B (+11% vs a year earlier) | — | +3.3% | +3.1% |
| May 1, 2023 | ended Mar 2023 | $4.8B (+12% vs a year earlier) | — | −1.9% | −3.8% |
| Jan 31, 2023 | ended Dec 2022 | $5.2B (+11% vs a year earlier) | — | +11.8% | +9.2% |
| Oct 31, 2022 | ended Sep 2022 | $4.5B (+8% vs a year earlier) | — | −4.0% | −6.9% |
| Jul 26, 2022 | ended Jun 2022 | $4.5B (+5% vs a year earlier) | — | +5.1% | +5.8% |
| Apr 28, 2022 | ended Mar 2022 | $4.3B (+8% vs a year earlier) | — | −3.2% | −3.1% |
| Jan 27, 2022 | ended Dec 2021 | $4.7B (+10% vs a year earlier) | — | +0.1% | +1.0% |
Change in closing price from the first day shown, or with Price the closing price itself. Prices: Yahoo Finance, to Nov 12, 2026. Dashed lines: the days the company released earnings (its SEC 8-K filings); EPS estimates: Yahoo Finance. The stock's move after a release runs from the last close before its day to the close the day after (or five days after), so a release before the open counts like one after the close.
Is the business growing?
Revenue was $6.5B in the quarter ended Sep 2026, up 8% from a year earlier.
Show the data
| Quarter ended | Revenue | vs a year earlier |
|---|---|---|
| Dec 2022 | $5.2B | +11% |
| Mar 2023 | $4.8B | +12% |
| Jun 2023 | $5.0B | +11% |
| Sep 2023 | $4.9B | +10% |
| Dec 2023 | $5.8B | +12% |
| Mar 2024 | $5.2B | +10% |
| Jun 2024 | $5.4B | +9% |
| Sep 2024 | $5.5B | +12% |
| Dec 2024 | $6.4B | +11% |
| Mar 2025 | $5.9B | +12% |
| Jun 2025 | $6.0B | +11% |
| Sep 2025 | $6.1B | +10% |
| Dec 2025 | $7.2B | +11% |
| Mar 2026 | $6.0B | +3% |
| Jun 2026 | $6.6B | +9% |
| Sep 2026 | $6.5B | +8% |
Revenue went from $18.4B in FY22 to $25.1B in FY25; net income from $2.4B to $3.2B.
Show the data
| Fiscal year | Revenue | Net income |
|---|---|---|
| FY22 | $18.4B | $2.4B |
| FY23 | $20.5B | $3.2B |
| FY24 | $22.6B | $3.0B |
| FY25 | $25.1B | $3.2B |
In the fiscal year to Dec 2025, United States was 76% and Europe, Middle East, Africa was 13% of revenue.
Show the data
| Fiscal year | Part | Revenue | Share |
|---|---|---|---|
| FY2023 | United States | $15.3B | 74% |
| FY2023 | Europe, Middle East, Africa | $2.6B | 13% |
| FY2023 | Asia Pacific | $1.9B | 9% |
| FY2023 | Other foreign countries | $677M | 3% |
| FY2024 | United States | $16.9B | 75% |
| FY2024 | Europe, Middle East, Africa | $2.9B | 13% |
| FY2024 | Asia Pacific | $2.0B | 9% |
| FY2024 | Other foreign countries | $735M | 3% |
| FY2025 | United States | $19.0B | 76% |
| FY2025 | Europe, Middle East, Africa | $3.2B | 13% |
| FY2025 | Asia Pacific | $2.2B | 9% |
| FY2025 | Other foreign countries | $765M | 3% |
A year earlier $2.22
Diluted, from SEC filings
The P/E of 33.3× over the 23% EPS growth of the last four quarters; near 1 or below is cheap for the growth
Quarters: Stryker Corporation's SEC filings, named by the month they end. Fiscal years: Stryker Corporation's annual reports to the SEC.
How it makes money
Of every $100 in revenue, $12.9 ends up as net income. Net margin was roughly flat over the past 3 years.
Show the data
| Quarter ended | Gross | Operating | Net |
|---|---|---|---|
| Dec 2022 | 62.2% | 15.6% | 10.8% |
| Mar 2023 | 63.1% | 15.4% | 12.4% |
| Jun 2023 | 63.7% | 19.3% | 14.8% |
| Sep 2023 | 64.3% | 19.0% | 14.1% |
| Dec 2023 | 63.7% | 21.6% | 19.7% |
| Mar 2024 | 63.6% | 18.5% | 15.0% |
| Jun 2024 | 63.0% | 19.4% | 15.2% |
| Sep 2024 | 64.0% | 19.7% | 15.2% |
| Dec 2024 | 64.9% | 9.0% | 8.5% |
| Mar 2025 | 63.8% | 14.3% | 11.1% |
| Jun 2025 | 63.8% | 18.5% | 14.7% |
| Sep 2025 | 63.6% | 18.7% | 14.2% |
| Dec 2025 | 64.5% | 25.2% | 11.8% |
| Mar 2026 | 63.3% | 15.5% | 12.4% |
| Jun 2026 | 68.3% | 25.2% | 19.4% |
| Sep 2026 | 65.2% | 15.9% | 11.5% |
Circled: Dec 2025 (net 11.8%, operating 25.2%). Net margin is usually about 4 points below operating margin; in that quarter something below operating income (a tax charge or benefit, a gain or loss on investments, a write-down) moved it, not the business itself.
+1.2 pts over 3 years
+4.1 pts over 3 years
Roughly flat over 3 years
Each margin is that line of the income statement divided by revenue. Fiscal year: Stryker Corporation's annual reports to the SEC; quarters: SEC filings.
How much goes into research?
Stryker spent $1.7B on research and development in the four quarters to Sep 2026, 6.4% of its revenue, against 6.5% a year earlier. Over the year its research spending rose 6.4% and its revenue rose 7.9%.
Up 6.4% on the four quarters before
6.5% a year earlier
Show the data
| Quarter ended | Research and development | Revenue | Share of revenue, four quarters |
|---|---|---|---|
| Dec 2023 | $350M | $5.8B | 6.8% |
| Mar 2024 | $368M | $5.2B | 6.8% |
| Jun 2024 | $363M | $5.4B | 6.7% |
| Sep 2024 | $377M | $5.5B | 6.6% |
| Dec 2024 | $358M | $6.4B | 6.5% |
| Mar 2025 | $405M | $5.9B | 6.5% |
| Jun 2025 | $407M | $6.0B | 6.5% |
| Sep 2025 | $410M | $6.1B | 6.5% |
| Dec 2025 | $401M | $7.2B | 6.5% |
| Mar 2026 | $413M | $6.0B | 6.5% |
| Jun 2026 | $434M | $6.6B | 6.4% |
| Sep 2026 | $433M | $6.5B | 6.4% |
From Stryker Corporation's SEC filings: research and development expense by quarter, the fourth being the year minus nine months; its share is the four quarters' expense over their revenue. Some companies count the research they buy, through licences and acquisitions, in this line, so it jumps in the quarter they pay; others report that on a line of its own, not shown here.
Is it expensive?
P/E of 33.3x, above the peer median of 24.8x, so it needs earnings to keep growing to hold up.
Priced 34% above the peer median of 24.8x.
Show the data
| Company | P/E (trailing) |
|---|---|
| EW · Edwards Lifesciences Corporation | 61.5× |
| ABT · Abbott Laboratories | 39.9× |
| SYK · Stryker Corporation | 33.3× |
| MDT · Medtronic plc | 24.8× |
| BSX · Boston Scientific Corporation | 18.7× |
| GEHC · GE HealthCare Technologies Inc. | 17.3× |
At 33.3× trailing earnings SYK is below most of its five-year range; the five-year median is 41.9×.
Show the data
| Date | Trailing P/E |
|---|---|
| Nov 8, 2021 | 55.4× |
| Feb 8, 2022 | 49.0× |
| May 10, 2022 | 43.3× |
| Aug 10, 2022 | 40.4× |
| Nov 8, 2022 | 32.6× |
| Feb 9, 2023 | 42.8× |
| May 11, 2023 | 41.5× |
| Aug 11, 2023 | 39.8× |
| Nov 9, 2023 | 40.2× |
| Feb 12, 2024 | 41.3× |
| May 13, 2024 | 37.1× |
| Aug 13, 2024 | 36.7× |
| Nov 11, 2024 | 40.6× |
| Feb 13, 2025 | 50.0× |
| May 15, 2025 | 53.0× |
| Aug 15, 2025 | 50.6× |
| Nov 13, 2025 | 49.1× |
| Feb 17, 2026 | 43.9× |
| May 18, 2026 | 36.3× |
| Aug 18, 2026 | 34.3× |
| Nov 12, 2026 | 33.3× |
Closing price over diluted earnings per share of the last four reported quarters, as known on each day (a quarter counts 35 days after it ends). From SEC filings; earnings per share adjusted for splits.
What analysts expect
The average analyst price target is $340, 9% above the current price; 73% of 30 analysts rate it a buy; earnings beat estimates in 2 of the last 4 quarters.
Buy or Strong Buy: 22 analysts (73%). Sell or Strong Sell: 0.
Over the past year the average of the analysts' latest price targets went from $428.50 to $341.38 (−20%), while SYK went from $373.42 to $312.39 (−16%). In the past three months targets were raised once and cut 19 times. 1 upgrade and 2 downgrades over the year; the latest: Canaccord Genuity moved it to Hold from Buy on Oct 30, 2026.
Show every change
| Date | Firm | Change | Rating | Target |
|---|---|---|---|---|
| Nov 9, 2026 | Piper Sandler | Target raised | Overweight | $350.00, was $325.00 |
| Nov 2, 2026 | Truist Securities | Target cut | Hold | $305.00, was $310.00 |
| Nov 2, 2026 | Stifel | Target cut | Buy | $325.00, was $330.00 |
| Oct 31, 2026 | JP Morgan | Target cut | Overweight | $340.00, was $350.00 |
| Oct 30, 2026 | Citigroup | Target cut | Buy | $315.00, was $360.00 |
| Oct 30, 2026 | TD Cowen | Target cut | Hold | $290.00, was $298.00 |
| Oct 30, 2026 | RBC Capital | Target cut | Outperform | $375.00, was $420.00 |
| Oct 30, 2026 | Barclays | Target cut | Overweight | $365.00, was $375.00 |
| Oct 30, 2026 | Canaccord Genuity | Downgrade | Hold, was Buy | $300.00, was $385.00 |
| Oct 30, 2026 | Citizens | Target cut | Market Outperform | $390.00, was $400.00 |
| Oct 30, 2026 | Evercore ISI Group | Target cut | Outperform | $320.00, was $335.00 |
| Oct 30, 2026 | Needham | Target cut | Buy | $359.00, was $418.00 |
| Oct 30, 2026 | BTIG | Target cut | Buy | $304.00, was $316.00 |
| Oct 12, 2026 | BTIG | Target cut | Buy | $316.00, was $358.00 |
| Oct 7, 2026 | Truist Securities | Target cut | Hold | $310.00, was $340.00 |
| Oct 7, 2026 | Barclays | Began coverage | Overweight | $375.00 |
| Sep 30, 2026 | Stifel | Target cut | Buy | $330.00, was $360.00 |
| Sep 22, 2026 | TD Cowen | Target cut | Hold | $298.00, was $355.00 |
| Sep 18, 2026 | Canaccord Genuity | Target cut | Buy | $385.00, was $400.00 |
| Sep 10, 2026 | Citigroup | Target cut | Buy | $360.00, was $399.00 |
| Sep 9, 2026 | Wells Fargo | Target cut | Overweight | $348.00, was $418.00 |
| Aug 13, 2026 | Wolfe Research | Downgrade | Peer Perform, was Outperform | — |
| Aug 3, 2026 | Citizens | Target cut | Market Outperform | $400.00, was $440.00 |
| Jul 31, 2026 | RBC Capital | Target cut | Outperform | $420.00, was $435.00 |
| Jul 31, 2026 | JP Morgan | Target cut | Overweight | $350.00, was $400.00 |
| Jul 31, 2026 | Piper Sandler | Target cut | Overweight | $390.00, was $420.00 |
| Jul 31, 2026 | Truist Securities | Target raised | Hold | $340.00, was $330.00 |
| Jul 31, 2026 | BTIG | Target cut | Buy | $358.00, was $371.00 |
| Jul 9, 2026 | BMO Capital | Began coverage | Outperform, was Market Perform | $369.00 |
| Jul 6, 2026 | Evercore ISI Group | Target cut | Outperform | $350.00, was $355.00 |
| Jun 5, 2026 | Leerink Partners | Target cut | Outperform | $407.00, was $410.00 |
| May 4, 2026 | Truist Securities | Target cut | Hold | $330.00, was $380.00 |
| May 4, 2026 | Barclays | Target cut | Overweight | $394.00, was $469.00 |
| May 1, 2026 | Canaccord Genuity | Target cut | Buy | $400.00, was $435.00 |
| May 1, 2026 | JP Morgan | Target cut | Overweight | $400.00, was $445.00 |
| May 1, 2026 | Evercore ISI Group | Target cut | Outperform | $355.00, was $365.00 |
| May 1, 2026 | Wells Fargo | Target cut | Overweight | $418.00, was $456.00 |
| May 1, 2026 | Needham | Target cut | Buy | $418.00, was $454.00 |
| May 1, 2026 | BTIG | Target cut | Buy | $379.00, was $397.00 |
| Apr 15, 2026 | Truist Securities | Target cut | Hold | $380.00, was $395.00 |
| Apr 14, 2026 | BTIG | Target kept | Buy | $397.00 |
| Apr 13, 2026 | Leerink Partners | Began coverage | Outperform | $410.00 |
| Apr 9, 2026 | Goldman Sachs | Target cut | Neutral | $357.00, was $403.00 |
| Apr 7, 2026 | Citigroup | Target cut | Buy | $385.00, was $420.00 |
| Apr 6, 2026 | Evercore ISI Group | Target cut | Outperform | $365.00, was $400.00 |
| Mar 17, 2026 | UBS | Target cut | Neutral | $380.00, was $400.00 |
| Feb 24, 2026 | UBS | Target raised | Neutral | $400.00, was $386.00 |
| Feb 2, 2026 | Barclays | Target raised | Overweight | $469.00, was $462.00 |
| Jan 30, 2026 | Needham | Target raised | Buy | $454.00, was $448.00 |
| Jan 30, 2026 | BTIG | Target raised | Buy | $412.00, was $410.00 |
| Jan 9, 2026 | Bernstein | Target raised | Outperform | $465.00, was $450.00 |
| Dec 19, 2025 | Citizens | Upgrade | Market Outperform, was Market Perform | $440.00 |
| Dec 18, 2025 | Truist Securities | Target cut | Hold | $392.00, was $400.00 |
| Dec 11, 2025 | Citigroup | Target cut | Buy | $420.00, was $455.00 |
| Nov 14, 2025 | Truist Securities | Target raised | Hold | $400.00, was $392.00 |
| Nov 14, 2025 | Wells Fargo | Target raised | Overweight | $456.00, was $452.00 |
| Nov 14, 2025 | Needham | Target kept | Buy | $448.00 |
| Nov 14, 2025 | BTIG | Target kept | Buy | $410.00 |
Show the data
| Quarter | Estimate | Reported | Surprise |
|---|---|---|---|
| Dec ’25 | $4.40 | $4.47 | +1.6% |
| Mar ’26 | $2.98 | $2.60 | −12.8% |
| Jun ’26 | $3.49 | $3.69 | +5.7% |
| Sep ’26 | $3.55 | $3.52 | −0.8% |
The day after each of these reports the stock moved +3.3% (Dec 2025, beat); −6.5% (Mar 2026, missed); −7.5% (Jun 2026, beat); −4.0% (Sep 2026, missed).
For the quarter ending Dec 2026 (Stryker reports on Jan 28, 2027), analysts expect adjusted earnings of $5.02 a share, 12% more than the $4.47 of a year earlier, and revenue of $7.7B, up 7% on a year earlier. For the fiscal year ending Dec 2027, they expect adjusted earnings of $16.29 a share, 10% more than the year before's estimate of $14.83, and revenue of $28.8B, up 7% on the year before's estimate.
Adjusted. Dec 2025: $4.47; range $4.99 to $5.05; 25 analysts
Dec 2025: $7.2B; range $7.6B to $7.8B; 24 analysts
Adjusted. The year to Dec 2026: $14.83 expected; range $16.00 to $16.51; 29 analysts
The year to Dec 2026: $26.8B expected; range $28.3B to $31.8B; 28 analysts
Show the data
| Period | Figure | Expected | Low to high | Analysts | A year earlier | Change |
|---|---|---|---|---|---|---|
| Quarter ending Dec 2026, results Jan 28, 2027 | EPS (adjusted) | $5.02 | $4.99 to $5.05 | 25 | $4.47 (Dec 2025) | +12% |
| Quarter ending Dec 2026, results Jan 28, 2027 | Revenue | $7.7B | $7.6B to $7.8B | 24 | $7.2B (Dec 2025) | +7% |
| Quarter ending Mar 2027 | EPS (adjusted) | $3.18 | $2.83 to $3.63 | 16 | $2.60 (Mar 2026) | +22% |
| Quarter ending Mar 2027 | Revenue | $6.5B | $6.4B to $6.7B | 14 | $6.0B (Mar 2026) | +8% |
| Year ending Dec 2026 | EPS (adjusted) | $14.83 | $14.80 to $14.88 | 29 | — | — |
| Year ending Dec 2026 | Revenue | $26.8B | $26.7B to $26.9B | 26 | $25.1B (year to Dec 2025) | +7% |
| Year ending Dec 2027 | EPS (adjusted) | $16.29 | $16.00 to $16.51 | 29 | $14.83 (expected, year to Dec 2026) | +10% |
| Year ending Dec 2027 | Revenue | $28.8B | $28.3B to $31.8B | 28 | $26.8B (expected, year to Dec 2026) | +7% |
Targets, ratings and earnings estimates: Yahoo Finance. Rating and target changes: Yahoo Finance's list of upgrades and downgrades. The average target on each day is the average of every listed firm's latest target set in the 180 days before it, so it counts fewer analysts than the average target above, and the band is the middle half of those targets (a quarter of the firms are above it, a quarter below); a target set before a stock split is divided by the split. Expected figures: the average of the analysts' estimates (Yahoo Finance). Their EPS is adjusted, as analysts estimate it, so it is set against the adjusted EPS Yahoo reports for the same quarters, not the GAAP EPS of the growth and valuation sections; revenue against the SEC filings. No change is given against a quarter whose reported EPS was more than 50% off its own estimate (often a one-off gain or charge), nor against a year that counts one. Each estimate is pinned to its fiscal period by the report date or the period's end, and one that cannot be is left out.
Where the cash goes
Generated $4.6B in free cash flow over the year, of which $1.4B went back to shareholders (dividends plus buybacks), leaving $3.2B in the company.
Show the data
| Line | Amount |
|---|---|
| Op. cash flow | $5.4B |
| Capex | −$800M |
| Free cash flow | $4.6B |
| Dividends | −$1.3B |
| Buybacks | −$100M |
| Cash retained | $3.2B |
For every $100 of market cap, the company generates about $3.9 in free cash flow a year.
For every $100 of market cap, you receive about $1.1 in dividends a year.
Show the data
| Quarter ended | Free cash flow | Dividends | Buybacks |
|---|---|---|---|
| Dec 2023 | $1.4B | $285M | — |
| Mar 2024 | $37M | $304M | — |
| Jun 2024 | $481M | $305M | — |
| Sep 2024 | $1.3B | $305M | — |
| Dec 2024 | $1.7B | $305M | — |
| Mar 2025 | $127M | $320M | — |
| Jun 2025 | $928M | $321M | — |
| Sep 2025 | $1.4B | $322M | — |
| Dec 2025 | $1.9B | $321M | — |
| Mar 2026 | $415M | $337M | — |
| Jun 2026 | $1.1B | $337M | — |
| Sep 2026 | $1.2B | $338M | — |
Stryker had 385M diluted shares in the quarter ended Sep 2026, 0.5% fewer than a year earlier, and 0.4% more each year on average since Jun 2020. Over the last four quarters its earnings per share rose 23.4% and its net income rose 23.1%: fewer shares added about 0 points.
Show the data
| Quarter ended | Diluted shares |
|---|---|
| Jun 2020 | 376M |
| Sep 2020 | 380M |
| Mar 2021 | 382M |
| Jun 2021 | 382M |
| Sep 2021 | 383M |
| Mar 2022 | 383M |
| Jun 2022 | 382M |
| Sep 2022 | 382M |
| Mar 2023 | 383M |
| Jun 2023 | 384M |
| Sep 2023 | 384M |
| Mar 2024 | 385M |
| Jun 2024 | 385M |
| Sep 2024 | 386M |
| Mar 2025 | 386M |
| Jun 2025 | 386M |
| Sep 2025 | 387M |
| Mar 2026 | 386M |
| Jun 2026 | 386M |
| Sep 2026 | 385M |
Free cash flow: operating cash flow minus capital spending on property, plant and equipment, from SEC filings, for the last 4 quarters and by quarter. Shares: each quarter's diluted weighted average as filed with the SEC, since the stock's listing and its latest split.
Financial health
Current ratio 1.9, no pressure to repay short-term debt; debt-to-equity 0.7, debt is moderate.
Assets that can be turned into cash soon are 1.9x what is owed within a year. 1.5 or higher is comfortable; below 1 needs watching.
For every $1 of shareholder funds, there is $0.7 of debt. The higher the number, the more pressure when the economy weakens.
Cash and short-term investments of $4.1B against debt of $15.9B.
Latest fiscal year balance sheet. Source: Yahoo Finance.
Who holds it
In the filings of 3 members of Congress and 8 funds whose copy leaves SYK out (not traded on the exchange): Fundsmith, Tom Kean Jr., Jared Moskowitz, Rob Bresnahan, Norges Bank, Swiss National Bank and 5 more.
What did the funds Hunch tracks do?
Of the 83 funds whose 13F filings Hunch reads, 11 held SYK at the end of their latest quarter (for most, Q2 2026). Over that quarter 2 added shares, 8 cut, 1 bought new and 2 sold all. The largest of them is Norges Bank, 4.89M shares worth $1.5B at Jun 30, 2026, 5.6% fewer than at Dec 31, 2025.
1 of them new holders
2 of them sold all
Show every fund
| Fund | Quarter | Shares | Value | Change in shares | Change | Filed |
|---|---|---|---|---|---|---|
| Norges Bank | Q2 2026 vs Q4 2025 | 4.89M | $1.5B | −292,101 | −5.6% | Aug 12, 2026 |
| Fundsmith | Q2 2026 | 2.91M | $917M | −147,583 | −4.8% | Aug 14, 2026 |
| Swiss National Bank | Q3 2026 | 943,740 | $260M | −28,440 | −2.9% | Nov 12, 2026 |
| National Pension Service | Q3 2026 | 730,799 | $201M | +9,613 | +1.3% | Nov 12, 2026 |
| Canada Pension Plan Investment Board | Q2 2026 | 488,517 | $154M | −60,113 | −11% | Aug 14, 2026 |
| Fisher Asset Management | Q3 2026 | 378,378 | $104M | −17,396 | −4.4% | Nov 6, 2026 |
| Korea Investment | Q2 2026 | 170,682 | $53.7M | −4,898 | −2.8% | Aug 12, 2026 |
| Renaissance Technologies | Q3 2026 | 0 | — | −91,300 | Sold all | Nov 12, 2026 |
| Mirae Asset Global Investments | Q3 2026 | 94,280 | $26.0M | −15,133 | −14% | Nov 3, 2026 |
| Baillie Gifford & | Q3 2026 | 62,615 | $17.2M | +62,615 | New | Nov 9, 2026 |
| Nomura Holdings | Q2 2026 | 21,150 | $6.7M | +19,816 | +1485% | Aug 14, 2026 |
| Bridgewater Associates | Q2 2026 | 12,155 | $3.8M | −14,255 | −54% | Aug 14, 2026 |
| Tudor Investment Corp Et Al | Q2 2026 | 0 | — | −1,370 | Sold all | Aug 14, 2026 |
From the 13F filings of the 83 funds Hunch tracks, not of every institution: each fund's shares of SYK at its latest quarter end against the quarter before, as filed (long positions only, options left out), the quarter before put on the latest quarter's share count across a split. A fund files 45 days after its quarter ends, so some have a newer quarter than others. Value is at the quarter end. Norges Bank filed its 13F for Q1 2026 confidentially, with no holdings made public, so its row compares Q2 2026 with Q4 2025.